Boundless Bio, Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.96M | 4.63M | 4.66M | 3.75M | 3.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.28M | 18.72M | 19.39M | 16.88M | 13.80M |
| Operating Income | -18.28M | -18.72M | -19.39M | -16.88M | -13.80M |
| Income Before Tax | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
| EBIT | -18.28M | -18.72M | -19.39M | -16.88M | -13.80M |
| EBITDA | -17.98M | -18.45M | -19.13M | -16.62M | -13.55M |
| EPS Basic | -0.74 | -0.74 | -0.77 | -12.27 | -9.77 |
| Normalized Basic EPS | -0.46 | -0.46 | -0.48 | -7.67 | -6.11 |
| EPS Diluted | -0.74 | -0.74 | -0.77 | -12.27 | -9.77 |
| Normalized Diluted EPS | -0.46 | -0.46 | -0.48 | -7.67 | -6.11 |
| Average Basic Shares Outstanding | 22.28M | 22.25M | 22.02M | 1.26M | 1.24M |
| Average Diluted Shares Outstanding | 22.28M | 22.25M | 22.02M | 1.26M | 1.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |